Success Metrics

Clinical Success Rate
97.3%

Based on 36 completed trials

Completion Rate
97%(36/37)
Active Trials
2(4%)
Results Posted
25%(9 trials)
Terminated
1(2%)

Phase Distribution

Ph phase_2
5
11%
Ph not_applicable
2
4%
Ph phase_1
10
21%
Ph phase_3
3
6%

Phase Distribution

10

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
10(50.0%)
Phase 2Efficacy & side effects
5(25.0%)
Phase 3Large-scale testing
3(15.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

94.7%

36 of 38 finished

Non-Completion Rate

5.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

47

all time

Status Distribution
Active(2)
Completed(36)
Terminated(2)
Other(7)

Detailed Status

Completed36
unknown7
Active, not recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
47
Active
2
Success Rate
97.3%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (50.0%)
Phase 25 (25.0%)
Phase 33 (15.0%)
N/A2 (10.0%)

Trials by Status

completed3677%
terminated12%
active_not_recruiting24%
unknown715%
withdrawn12%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT00977457Phase 1

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

Active Not Recruiting
NCT01149850Phase 2

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed
NCT00382200Phase 1

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed
NCT05004090

Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience

Unknown
NCT00626990Phase 3

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Active Not Recruiting
NCT00900224

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Unknown
NCT00482677Phase 3

Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
NCT01673217Phase 1

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed
NCT01290939Phase 3

Bevacizumab and Lomustine for Recurrent GBM

Completed
NCT01155583Phase 1

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Completed
NCT00601289Phase 2

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Withdrawn
NCT00897936

DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia

Completed
NCT00691652Phase 1

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Terminated
NCT00899548

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

Completed
NCT01165996Phase 1

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed
NCT00770471Phase 1

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
NCT01414595

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

Completed
NCT00897819

Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200

Completed
NCT01421875

Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia

Completed
NCT01209299

Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

Completed

Drug Details

Intervention Type
GENETIC
Total Trials
47